Figure 2.

Kaplan–Meier curves for overall survival (A) and progression-free survival (B) in the study population.

Notes: The hazard ratio (HR) for overall survival at final analysis was 0.79 (95% CI: 0.66–0.94; P=0.0038). Reprinted from The Lancet, 381, Grothey et al, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, 303–312, Copyright © 2013, with permission from Elsevier.¹¹

Abbreviations: CI, confidence interval; IQR, interquartile range; PFS, progression-free survival.